Benzinga · Nov 9, 2026
JP Morgan Maintains Neutral on Chemours, Lowers Price Target to $14
JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $15 to $14.
NYSE · CC
Basic Materials · Chemicals - Specialty
$12.48
Down-$0.72 (-5.47%)
Updated Nov 17, 2026, 2:38 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
CC closed at $12.48 after 21 trading sessions, down 1.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $12.94 | $13.055 | $12.405 | $12.48 | 1.6M |
| Nov 13, 2026 | $13.37 | $13.48 | $12.96 | $13.29 | 1.4M |
| Nov 12, 2026 | $13.56 | $13.68 | $13.29 | $13.35 | 960.31K |
| Nov 11, 2026 | $13.74 | $13.98 | $13.58 | $13.72 | 1.5M |
| Nov 10, 2026 | $13.08 | $13.58 | $12.79 | $13.48 | 1.84M |
| Nov 9, 2026 | $12.94 | $13.465 | $12.7901 | $13.28 | 3.44M |
| Nov 6, 2026 | $12.64 | $12.875 | $12.40 | $12.75 | 3.7M |
| Nov 5, 2026 | $13.70 | $13.94 | $12.565 | $12.75 | 3.59M |
| Nov 4, 2026 | $13.32 | $14.11 | $13.285 | $13.79 | 4.01M |
| Nov 3, 2026 | $14.48 | $14.48 | $13.04 | $13.09 | 2.98M |
| Nov 2, 2026 | $13.66 | $13.81 | $13.15 | $13.16 | 4.48M |
| Oct 30, 2026 | $12.96 | $13.575 | $12.95 | $13.53 | 2.16M |
| Oct 29, 2026 | $13.35 | $13.47 | $13.04 | $13.19 | 1.47M |
| Oct 28, 2026 | $13.22 | $13.48 | $13.095 | $13.36 | 1.33M |
| Oct 27, 2026 | $13.00 | $13.365 | $12.95 | $13.34 | 2.64M |
| Oct 26, 2026 | $12.80 | $13.37 | $12.71 | $12.87 | 1.9M |
| Oct 23, 2026 | $12.99 | $13.08 | $12.575 | $12.81 | 1.7M |
| Oct 22, 2026 | $12.76 | $13.08 | $12.66 | $13.03 | 2.42M |
| Oct 21, 2026 | $13.07 | $13.07 | $12.795 | $12.94 | 2.4M |
| Oct 20, 2026 | $12.56 | $13.06 | $12.52 | $12.97 | 2.98M |
| Oct 19, 2026 | $12.80 | $12.89 | $12.55 | $12.62 | 2.14M |
The latest Smart Investors Daily articles mentioning CC.
Company
Market Activity
Research & News
CC research
Company profile and research snapshot.
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 9, 2026 | JP Morgan | Neutral | — |
| Nov 4, 2026 | UBS | Neutral | — |
| Nov 4, 2026 | Truist Securities | Buy | — |
| Oct 20, 2026 | Truist Securities | Buy | — |
| Oct 14, 2026 | Mizuho | Neutral | — |
No generated briefing is available yet.
Benzinga · Nov 9, 2026
JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $15 to $14.
Yahoo · Nov 8, 2026
Chemours has seen its share price struggle over longer periods, yet fresh product launches and recent sales figures keep pulling attention back to one basic question for investors: Is the current US$12.75 share price properly anchored in what the company is generating from its sales line today? The share price has fallen 54.9% over the past 5 years, which puts extra weight on whether the current market value can still be explained by its revenue base. The rollout of Faizeon cooling solutions...
Yahoo · Nov 8, 2026
Chemours reported past third quarter 2026 results with US$1,540 million in sales and US$196 million in net income, alongside a class action lawsuit alleging overstated Opteon demand and unreliable financial guidance. The lawsuit targets Chemours' prior commentary on aftermarket refrigerant demand and guidance quality, which cuts directly to investor confidence in how management frames business conditions and future expectations. The next focus will be on how Chemours' investment narrative...
Yahoo · Nov 7, 2026
Chemours (CC) just paired a sharp third quarter profit improvement with fresh guidance and a new Faizeon liquid cooling line for AI and high performance computing, giving investors several moving pieces to weigh. Recent action around Chemours reflects a mix of excitement and caution. The share price has risen 4.1% year to date, but the 30 day share price return is down 8.8% and the 90 day share price return is down 19.1%, while the 5 year total shareholder return has fallen 54.9%. Momentum...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CC.